The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO).
 
Tira Jing Ying Tan
Consulting or Advisory Role - Novartis; Pfizer
Research Funding - Bayer; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Merck Sharp & Dohme; Pfizer
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Merck; Novartis
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
David Hogg
No Relationships to Disclose
 
Adrian G. Sacher
Honoraria - AstraZeneca; Genentech/Roche; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gritstone Bio; Pfizer
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst); SignalChem (Inst)
 
Kendra Ross
No Relationships to Disclose
 
Helen Chow
No Relationships to Disclose
 
Aida Al-Kindy
No Relationships to Disclose
 
Sarah Boross-Harmer
No Relationships to Disclose
 
Wei Xu
No Relationships to Disclose
 
Bryan Coburn
Other Relationship - Nubiyota
 
Lillian L. Siu
Leadership - Agios (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Loxo; Merck; MorphoSys; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Anna Spreafico
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck; Northern Biologics; Novartis; Surface Oncology; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Merck